Thalmann GN, Rhee H, Sikes RA, Pathak S, Multani A, Zhau HE et al
(2022) demonstrated Cerebrolysin's effects on Alzheimer's disease biomarkers in a randomized controlled trial, providing objective biological evidence for its neurotrophic activity (PMID: 36155516) Regulatory Validation: Approved for clinical use in over 40 countries for indications including stroke, traumatic brain injury, and dementia (though not FDA-approved in the United States) Dihexa: Preclinical Only, with Integrity Concerns Dihexa's evidence base is entirely preclinical and has faced significant scientific integrity challenges: Foundational Research: Wright et al
Elmore AR, Adhikari N, Hartley AE, Aparicio HJ, Posner DC, Hemani G, et al
~ AlphaMD Anastrozole is not automatically necessary when taking less than 200 mg of testosterone per week
Nonprotein thiols and disulfides in rat epididymal spermatozoa and epididymal fluid: Role of gamma-glutamyl-transpeptidase in sperm maturation